|
Aug 12
|
GILD Q2 Deep Dive: HIV Franchise Drives Growth, New Launches and Pipeline in Focus
|
|
Aug 12
|
Gilead Receives Favorable CHMP Opinion For HIV Prevention With Twice-Yearly Lenacapavir
|
|
Aug 11
|
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
|
|
Aug 11
|
Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update
|
|
Aug 11
|
Company News for Aug 11, 2025
|
|
Aug 11
|
Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.
|
|
Aug 9
|
Gilead Sciences (GILD) Touches New Record High as 10 Analysts Turn Bullish
|
|
Aug 9
|
Gilead Sciences Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 8
|
Nasdaq posts record closing high with tech gains, rate cut optimism
|
|
Aug 8
|
S&P 500 Gains and Losses Today: Apple Stock Extends Its Rise; The Trade Desk Craters After Earnings
|
|
Aug 8
|
These Stocks Moved the Most Today: Trade Desk, Expedia, SoundHound, Pinterest, Gilead, Peloton, and More
|
|
Aug 8
|
How major US stock indexes fared Friday, 8/8/2025
|
|
Aug 8
|
Gilead Surges 8%, Flirting With A Breakout, On Growing Enthusiasm For HIV PrEP
|
|
Aug 8
|
Equity Markets Rise After Corporate Earnings; Fed's Musalem Sees Labor, Inflation Risks
|
|
Aug 8
|
Gilead’s Yeztugo sales “ahead of expectations” following launch
|
|
Aug 8
|
Why Is Gilead Sciences (GILD) Stock Rocketing Higher Today
|
|
Aug 8
|
Gilead Sciences Expected to See 3% Growth in Annual HIV Product Sales, Truist Says
|
|
Aug 8
|
Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears
|
|
Aug 8
|
Reason to worry the Fed won't cut rates after all
|
|
Aug 8
|
Trade Desk downgraded, Instacart upgraded: Wall Street's top analyst calls
|